Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

Weill Cornell Medicine (WCM) logo

Weill Cornell Medicine (WCM)

Status and phase

Active, not recruiting
Phase 2


Prostate Cancer


Radiation: 20 days Radiation therapy (55 Gy in 20 fractions)
Radiation: 5 days Radiation Therapy (32.5 Gy in 5 fractions)

Study type


Funder types




Details and patient eligibility


The purpose of this study is to compare urinary and bowel side effects of hypofractionated radiotherapy in 20 treatments (4 weeks) to ultra-hypofractionated radiotherapy in 5 treatments (2 weeks) for prostate cancer that has returned after prostatectomy. The investigators are also interested in looking at time to progression and the quality of life (health scores).

Full description

The standard treatment for most patients with biochemical recurrence after radical prostatectomy is salvage radiotherapy. Salvage radiotherapy delays the need for chronic, non-curative treatment, such as long-term androgen suppression, and is the only potentially curative treatment of some biochemical recurrences after prostatectomy. Patients are recommended to undergo salvage radiotherapy to eradicate biochemical disease delivered in approximately 40 treatments over the course of 8 weeks, representing a high burden of therapy, which may be related to lower utilization of salvage radiotherapy. Modern radiotherapy for prostate cancer has been afforded many advantages including advanced image-guided radiotherapy allowing for larger dose delivery in fewer treatments and smaller margins with hypofractionated (20 treatments) and ultra-hypofractionated (5 treatments) radiotherapy. In patients that need salvage radiotherapy, the potential advantages of hypofractionated and ultra-hypofractionated radiotherapy delivered over 20 or 5 treatments are: 1) increased convenience to patients because of fewer treatment days, 2) reduced costs to patients because of reduced travel expenses and copays, 3) improved resource utilization for physicians because of the fewer number of treatments per patient and consequently 4) reduced cost to society. In prostate cancer specifically, hypofractionated and ultra-hypofractionated radiotherapy has the added potential of not increasing toxicity with shorter treatment times.


134 estimated patients




18 to 90 years old


No Healthy Volunteers

Inclusion criteria

  • Men aged 18 and older with histologically confirmed prostate cancer after prostatectomy with detectable PSA. PSA does not need to be detectable for men with pathologically node positive disease.
  • KPS >=70
  • Patient with no evidence of distant metastatic disease on PET/CT/MRI or bone scan < 9 months prior to enrollment. Patients with positive pelvic lymph nodes are eligible.
  • Ability to receive MRI-guided radiotherapy.
  • Equivocal evidence of metastatic disease outside the pelvis on standard imaging requires documented negative biopsy.
  • Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire.

Exclusion criteria

  • Prior history of receiving pelvic radiotherapy.
  • Patient with inflammatory bowel disease.
  • Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of ultra-hypofractionated radiotherapy.
  • History of bladder neck or urethral stricture.

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

134 participants in 2 patient groups

ARM 1 - 2 weeks
Active Comparator group
Patients will receive treatment to the prostate fossa +/- nodes in 32.5 Gy in 5 fractions. Patients receiving 32.5 Gy in 5 fractions cannot be treated on consecutive days.
Radiation: 5 days Radiation Therapy (32.5 Gy in 5 fractions)
ARM 2 - 4 weeks
Active Comparator group
Patients will receive treatment to the prostate fossa +/- nodes in 55 Gy in 20 fractions.
Radiation: 20 days Radiation therapy (55 Gy in 20 fractions)

Trial contacts and locations



Central trial contact

Pragya Yadav, Ph.D.; Sharanya Chandrasekhar, M.S.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems